Summary NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Prevention and Control (CPC) priorities that will provide data that will directly lead to future Phase II-III CPC concepts. As put forward in our core grant, CPC priorities for funding include cancer prevention research and cancer control investigation aimed at understanding and/or ameliorating the symptoms and toxicity related to:
Integral to these priorities, are the establishment of biospecimen repositories for molecular studies.
Funding can be requested for up to $18,000 and is contingent upon NRG Oncology’s receipt of the Notice of Award from the Division of Cancer Prevention. One to two projects may be funded. Projects are to be implemented September 1, 2018 and completed by December 31, 2019. No carry over funds will be issued and an interim progress report is due within 6 months and a completed progress report is due at the end of the project period. Institutions who allow total award to fund research (and waive in-directs) will be given priority.
Background The NRG NCORP core grant focuses on continued leadership in cancer prevention and control (CPC) research. Our CPC objectives will benefit the NCTN Program through continued research across the breadth of NRG disease sites with a unique focus in both women's health, attributable to our gynecologic and breast cancer expertise, and technology assessment, through the world's largest radiotherapy (RT) focused research base. CPC will design and conduct trials to assess cancer prevention, reduce the burden of cancer treatment-related symptoms across solid tumor disease sites with an emphasis on the prevention of women's cancers, and a focus on high prevalence symptoms in our population.
Instructions for Applicants
If you have an interest in this application, please submit a [5
page proposal to firstname.lastname@example.org 5pm ET, Monday, April 16, 2018
Description of project, including summary of specific aims
How the project will help lead to a Phase II or Phase III NCORP concept